I N T H E N E W S
MEDIA & PRESS
We welcome enquiries from journalists, producers, and storytellers interested in accurate, evidence-based coverage of psychedelic science. If you are seeking expert comment, research insights, interviews, or background support, please get in touch. We are especially keen to support reporting that communicates psychedelic research clearly, responsibly, and in context.
-
![Cambridge Psychedelic Research Group (CPRG)]()
Worth the Wait: Cambridge Adds Its Voice to UK Psychedelic Science
12 April 2026
As it celebrates its first anniversary, the Cambridge Psychedelic Research Group (CPRG) is running multiple clinical trials with psychedelics, designing an MDMA-assisted study for anorexia nervosa, and developing group therapy models to make psychedelic-assisted treatment more accessible and scalable for health services in the UK. Psychedelic Alpha’s Charles Bliss reports…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Drug Science, Policy and Law – 2025 a year in review
28 February 2026
The psychedelic-assisted therapy landscape is changing rapidly. The clinical evidence for the use of MDMA and psilocybin continues to accumulate. Work overseen by Lykos Therapeutics demonstrated significant reductions in severe, treatment-resistant PTSD with MDMA-assisted therapy, and suggests potential indications for Alcohol Use Disorder and conflict-related trauma…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Your guide to Psychedelic-Assisted Therapy: Meet the people and compounds behind the startling therapeutic promise of psychedelics
29 October 2025
People are suffering. Recent polls suggest that 13% of Americans felt depressed in the 2 weeks prior to being asked, while 46% of EU citizens felt depressed or anxious in the last 12 months. If those figures are correct on a population level, then hundreds of millions of people are currently struggling with their mental health…
-
![Cambridge Psychedelic Research Group (CPRG)]()
The promise of psychedelic medicine in psychiatry
16 October 2025
After years of stigma, psychedelic compounds are edging closer to regulatory approval, with pivotal trials in tough-to-treat depression and anxiety underway. For decades, psychedelics were synonymous with counterculture and elicited fierce political backlash. Today, compounds derived from psychoactive substances such as psilocybin and lysergic acid diethylamide (LSD) are the subject of some of the most closely watched…
-
![Cambridge Psychedelic Research Group (CPRG)]()
‘There is a peak in psychosis among women around menopause, which isn’t talked about much due to the stigma’
14 October 2025
Liliana Galindo, 40, compares psychedelic therapies for mental health to surgery. “It’s a paradigm shift. Before, we used to administer daily medication, focused on treating symptoms that sometimes caused side effects and are expected to be taken for years. This type of therapy requires a significant initial investment because…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Meet the Cambridge researchers exploring psychedelic-assisted therapies
7 February 2025
The healing power of psychedelic compounds as spiritual tools has been recognised by many cultures for a large part of human history, from the use of ayahuasca by indigenous groups in the Western Amazon to the role of peyote and mescaline in Native American rituals. A new wave of research over the last 30 years has begun to investigate their potential for unlocking new psychological…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Cambridge officially launches research group to advance psychedelic-assisted therapy for mental health
30 April 2025
After several years in development, the Cambridge Psychedelic Research Group (CPRG) has officially launched to accelerate research into psychedelic-assisted therapy for mental health, both locally and nationally. The CPRG is a groundbreaking, multi-institutional partnership between the University of…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Researchers explore empathogens and psychedelics for PTSD treatment
17 October 2024
In a groundbreaking initiative to treat severe mental health conditions, a new research group in Cambridgeshire is conducting clinical trials to investigate the potential benefits of empathogens and psychedelics for PTSD treatment. Approximately 30% of individuals with severe mental illnesses find that conventional treatments are not effective enough. The trials aim to help…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Cambridge trials to assess empathogens and psychedelics
16 October 2024
People across Cambridgeshire and Peterborough with severe mental health conditions can now take part in groundbreaking clinical trials assessing the effects of empathogens and psychedelics. The trials aim to determine if these substances can aid those with treatment-resistant mental health conditions. The initiative has been set up by the new Cambridge Psychedelic Research group…
-
![Cambridge Psychedelic Research Group (CPRG)]()
Innovative mental health research partnership launches to study new therapies
10 October 2024
People across Cambridgeshire and Peterborough with severe mental health conditions now have the opportunity to take part in local groundbreaking clinical trials, to assess if empathogens and psychedelics can help people with treatment-resistant conditions. Around 30% of people with severe mental illness find standard mental health treatments do not work well enough…
F E A T U R E D W O R KCAMBRIDGE RESEARCH DAY
On 22 April 2026, the Cambridge Psychedelic Research Group hosted its 2nd Cambridge Psychedelics Research Day at Clare College, Cambridge. The event brought together over 170 clinicians, researchers, policymakers, and members of the public for a full day of lectures, panel discussions, and exchange on the latest developments in psychedelic science. Keynote speakers included Prof Guy Goodwin, Dr David Erritzøe, Prof Eric Vermetten, Prof Naomi Fineberg, Dr Reid Robison, Dr Chris Timmermann, Dr James Rucker, and Anya Ragnhildstveit.
The Cambridge Psychedelics Research Day is held annually at the University of Cambridge. To register your interest for 2027, or to learn more about past events, click here.
F E A T U R E D W O R KMDMA TRial for PTSD
On 24 April 2026, Sky News featured the Cambridge Psychedelic Research Group's upcoming clinical trial of MDMA-assisted group therapy for veterans, first responders, and war correspondents with PTSD. Reporting from Cambridge, the segment included interviews with Principal Investigator, Dr Liliana Galindo, and former British Army chief, Tom Swarbrick, who discussed his experience of living with PTSD and called on the Government to reschedule MDMA to help increase research access and treatment.
The trial, funded by Supporting Wounded Veterans and led by Dr Galindo, is anticipated to begin recruitment in 2027, subject to regulatory approvals. Read more about the partnership here.
D O W N L O A D A B L E A S S E S T SPRESS KIT & RESOURCES
CPRG Logo Pack
For all media enquiries, interview requests, and press materials
Research Summaries
One-pagers for each research study and programme.
Group Fact Sheet
Overview of CPRG, key stats, founding date, and affiliations.
Researcher Headshots
High-resolution photos of group members for publication use.
Interesting in speaking with our team?
For all media enquiries, interview requests, and press materials
D O N A T E T O D A Y Support our research
Our work is made possible by the generous support of philanthropists, industry partners, and private individuals. Their contributions enable us to conduct rigorous research, train the next generation of clinicians and scientists, and share accurate information about psychedelic therapy with the wider public.
To discuss a gift or learn how philanthropy shapes our work, please contact Belen Tejada-Romero, Head of Development — Brain and Mind Health, at the University of Cambridge.
